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Abstract: A late stage functionalization of the aromatic ring in amino acid derivatives 
is described. The key step is a copper-catalysed diversification of a boronate ester by 
amination (Chan-Lam reaction) that can be carried out on a complex -aryl--amino 
acid scaffold, and not only considerably extends the substrate scope of amination 
partners, but also delivers an array of potent and selective integrin inhibitors as 
potential treatments of idiopathic pulmonary fibrosis (IPF). This versatile chemistry 
strategy, which is amenable to high throughput array protocols, allows the installation 
of pharmaceutically valuable heteroaromatic fragments at a late stage by direct 
coupling to the NH heterocycles, leading to compounds with drug-like attributes, and 
is a useful addition to the medicinal chemist’s repertoire. 
 
Introduction 
Late stage functionalization (LSF) is a powerful tool in medicinal chemistry that 
enables rapid generation of highly diverse drug-like molecules from complex 
intermediates. This reduces overall step count, improving time and cost efficiency 
whilst maximizing diversity of chemical space exploration in lead optimization to 
elucidate structure-activity-relationships (SAR). The most frequently used reactions 
within medicinal chemistry are amide bond formations, Suzuki-Miyaura couplings, 
Buchwald-Hartwig couplings and SNAr reactions.[1] They are effective tools for 
introducing diversity, but are often unsuitable for LSF, due to forcing reaction 
conditions such as high temperatures, strong bases, expensive catalysts and complex 
ligands. On the other hand, C-H activation to install a variety of structural motifs at a 
late stage is a preferred tactic, although notwithstanding recent advances,[2] methods 
remain somewhat limited.  
Despite the fact that nitrogen-containing heterocycles are amongst the most 
prevalent cyclic structural features in small drug molecules, there are few examples of 
mild and robust aromatic C-N bond formation methods.[2] This is particularly pertinent 
for the installation of heteroaromatic 5-membered rings by direct coupling of the 
corresponding NH heterocycle, and therefore, methodology that is tolerant of a range 
of functional groups, but would allow the installation of these pharmaceutically 
valuable structural features at a late stage would be a welcome addition to the 
medicinal chemist’s inventory.[3] 
First reported in 1997,[4–6] the Chan-Lam amination that formally involves the 
coupling of two nucleophilic species has been characterized as capricious,[7] with the 
more commonplace Buchwald-Hartwig and Ullmann nucleophile-electrophile 
couplings subsequently gaining prominence in drug discovery.[1,8,9] However, due to 
limited substrate scope and harsh reaction conditions, neither of these are a viable 
methodology for LSF. In 2017, the mechanism of the Chan-Lam amination was 
elegantly elucidated by Vantourout et al.[10] The substrate scope, including both alkyl 
and aryl amines, and the improved reliability of the reaction, including its use in the 
synthesis of imatinib by a late stage amination,[10] thereby marked it as a potential 
methodology for LSF. Herein we report the first example of a more strategic LSF in 
drug discovery employing the Chan-Lam amination reaction that not only considerably 
extends the substrate scope of N-coupling partners, but also delivers an array of 
potent, selective (particularly vs. v1) and drug-like v6 integrin inhibitors as potential 
treatments of idiopathic pulmonary fibrosis (IPF). 
IPF is a chronic interstitial lung disease, characterized by excessive scarring of 
the interstitium. The incidence of IPF is estimated to be 4.6 per 100,000 and 6.8 per 
100,000 in the UK and the USA, respectively, with >5,000 and >14,000 people 
diagnosed each year.[11–13] IPF is fatal, with median survival rates of between two and 
four years.[13,14] Currently there are two approved treatments for the disease: 
pirfenidone 1 and nintedanib 2 (Figure 1). Both reduce the rate of lung function decline, 
although neither fully halts disease progression and various side effects are attributed 
to their use, leading to poor patient compliance.[15] 
 
 
Figure 1. Compounds used in the treatment of IPF; pirfenidone 1 and nintedanib 2. 
 
Transforming growth factor-beta(TGF-) is a key agent in the activation of 
fibroblasts,[16] the cells responsible for collagen deposition and the resulting build-up 
of scar tissue associated with IPF. Whilst direct inhibition of TGF- can lead to serious 
health complications,[17] it can be modulated sufficiently by inhibition of specific 
integrins. Integrins are heterodimeric cell surface receptors, composed of an  and  
subunit, that play roles in many cell adhesion processes.[18] A subset of eight integrins, 
from a total of 24 in vertebrates, recognize an arginine-glycine-aspartic acid (RGD) 
sequence motif in the latency associated peptide (LAP) that maintains a TGF-in an 
inactive form[19] At least two of these integrins, namely v6 and v8, activate TGF- 
by binding to the LAP (Figure 2), and expression of the v6 integrin in particular is 
elevated in IPF lung tissue compared to healthy tissue.[20] Thus, selective inhibition of 













Figure 2. Inhibition of the v6 integrin binding to LAP prevents the activation of TGF-.[20,21] 
 
Recently, an v6 antibody and the GSK candidate GSK3008348 3 have both been 
evaluated clinically,[22] and inhibition of the v6 integrin with 3 did not cause any 
adverse effects in healthy volunteers when dosed with 3-3000 g.[23] Inhibitor 3, and 
structurally similar compounds, are RGD mimetics, and such structures form the basis 
of our current work. 
 
Figure 3. The RGD tripeptide sequence, the clinical candidate 3 and the starting point for the current 
work, the pan-integrin inhibitor 4. Compounds are colored to show the structural similarities that mimic 
the basic and acidic sites in the RGD sequence by compounds 3 and 4. Selectivity and potency data 
from cell adhesion assays are shown.[24,25] 
 
Previous work in our group led to the development of a pan integrin inhibitor, the 3-
CF3-substituted--aryl--amino acid derivative 4, pan in this case referring to the fact 
that compound 4 exhibits broadly similar levels of potency towards multiple 
integrins.[24] Whilst compound (S)-4 displayed appropriate physiochemical properties 
(ChromLogD 2.73, permeability  >100 nm/s, aqueous solubility >300 M) and was 
therefore considered as lead-like, comparison with GSK3008348 3, and other 
analogues,[26,27] revealed significant differences in potency and selectivity (Figure 3). 
Therefore, in order to investigate whether the incorporation of an N-linked heterocycle 
resulted in increased potency in our own series, we set out to synthesize an array of 
analogues of the antagonist 4, using Chan-Lam amination LSF as the cornerstone of 
our strategy.  
 
Results and Discussion 
Of the two enantiomers of the CF3-compound 4, the activity has been demonstrated 
to reside in the (S)-enantiomer (Figure 3), and therefore the new N-linked analogues 

































rac avb6 pIC50 7.0
       avb3 pIC50 6.7
(S) avb6 pIC50 7.1
       avb3 pIC50 7.0
(R) avb6 pIC50 5.2
       avb3 pIC50 <5
reported by Ellman et al. was used to generate the (S)- -aminoester precursor via 
titanium tetra-isopropoxide mediated condensation of (R)-tert butyl sulfinamide with 
3-bromobenzaldehyde 5 to give (R)-sulfinimine 6, and subsequent Reformatsky 
reaction to give 7.[28] The Reformatsky reagent was formed in situ via treatment of 
tert-butyl bromoacetate with TMSCl activated zinc dust, generating the organozinc 
enolate. The pre-prepared sulfinimine 6 was subsequently added following cooling to 
0 °C, to minimize formation of the double addition product 8 (Scheme 1).[29] The (S)-
stereochemistry of the newly formed stereocentre in 7 was confirmed by X-ray 
crystallography (Figures 4 and S1, Supporting Information), and is in accord with that 
expected from the work reported by Ellman et al.[28] After selective removal of the 
sulfinamide functionality under acidic conditions, the amide 11 was formed by T3P 
mediated coupling of 9[30] with the Boc-protected-tetrahydro-1,8-naphthyridine-
pentanoic acid 10, the preparation of which is described in the literature.[31] The Boc-
protecting group was chosen so that it could be removed in concert with the tert-butyl 
ester after performing the array chemistry (q.v.).The key boronate intermediate 12 
was prepared in excellent yield from Miyaura borylation of 11 (Scheme 1). 
 
 





Scheme 1. Synthesis of key boronate intermediate 12. Reagents and Conditions: a) (R)-tert-butyl 
sulfinamide, Ti(OiPr)4, THF, rt; b) i) Zn, TMSCl, tert-butyl bromoacetate, THF, N2, reflux ii) 0 °C; c) HCl 
(4 M in 1,4-dioxane), diethyl ether, rt, 85% over three steps; d) 10, T3P, i-Pr2NEt, acetonitrile, 0 °C, 





























































Figure 5. Diversity of monomer amine coupling partners. Structures of pyrazoles, imidazoles, triazoles 
and cyclic secondary amines used in the Chan-Lam coupling reactions. Monomers are highlighted 
according to reaction outcome: green = successful coupling and product isolation; yields after mass-
directed auto purification (MDAP); black = successful coupling but unsuccessful product isolation; red 
= unsuccessful coupling.  a = yields of the separated regioisomers; b = amine used as the hydrochloride 
salt.   
 
A range of 58 highly diverse heteroaromatic (19 pyrazoles, 15 imidazoles, 8 triazoles) 
and 16 cyclic secondary amines (Figure 5) was selected to provide thorough 
exploration of chemical space within the specificity determining loop (SDL) in the 
integrin binding site.[22] Amines that would allow comparison between the resulting 
array compounds by single point changes were selected. Substituents within the 
amines were intentionally kept simple due to the lack of available SAR and therefore 
included small alkyl groups, halides and polar and non-polar hydrogen bond donors. 
To the best of our knowledge, there are few representative examples of Chan-Lam 
































































































































































































































7% 4/10%a 7/15%a 21% 40% 17% 4% 44% 37% 33%
13% 4/13%a 4% 4% 7% 5%
6% 21% 14% b 10% 30% 4% 35% 11%
15% 11% 12% b
22% 5% 15%
15% 22% 29% b b b b
5% 16% 4%b b
reported incorporate unsubstituted pyrazole, imidazole and benzimidazole parent 
rings.[6,10,32]  
The N-linked heterocyclic analogues were prepared in a high throughput array 
format. Reactions were performed in parallel in 4 mL vials in a 6 x 4 block placed upon 
a hotplate (see Supporting Information, General Preparation A), and utilized mass-
directed auto purification (MDAP) to allow rapid generation of diverse compounds to 
develop meaningful SARs. The inhibitor analogues were prepared via Chan-Lam 
amination between the boronate 12 and the selected amines on a 0.10 mmol scale, 
followed by global deprotection of both tert-butyl-based groups with TFA and 
subsequent isolation via MDAP (Scheme 2). Although isolated yields were often poor 
(<20%), this is due to the high UV threshold used by the MDAP method to maximize 
the chances of obtaining sample with high purity, which frequently results in significant 
loss of material. The yields of the Chan-Lam coupling were improved (45-52%) when 
the reaction was carried out on larger scale in batch format, albeit on the ethyl ester 
analogue of boronate 12, as described below for the coupling reactions of 3-chloro- 
and 3-isopropyl-pyrazoles and for piperidine. In the case of unsymmetrical 
heterocycles, two or more regioisomeric products can be formed and generally, the 
major regioisomer resulted from Chan-Lam coupling at the least sterically hindered 
nitrogen. In most cases, the major regioisomer was successfully separated from the 
minor regioisomer via MDAP, although some analogues were isolated as mixtures 
(see Supporting Information). Regioisomers were distinguishable by HSQCME NMR 
(see Supporting Information). 
 
 
Scheme 2. Array synthesis of integrin antagonists. Reagents and Conditions: a) N-H compounds (2.5 
eq), Cu(OAc)2 (1 eq), B(OH)3 (2 eq), acetonitrile, 3 Å MS, 70 °C; b) TFA, CH2Cl2, rt, 4-44% after MDAP 
purification. Structures of compounds 13-23 shown in Table 1; structures 37-64 shown in the Supporting 
Information. 
 
From the array of 58 NH coupling partners, 39 samples of sufficient purity (>85% by 
LCMS) for biological evaluation were isolated via MDAP (shown in green in Figure 5) 
(for details, see Supporting Information), including the minor regioisomer analogues 
from reaction with 3-methyl-, 3-fluoro- and 3,4-dimethyl-pyrazoles. Despite desired 
product being detected via LC/MS, the isolation of eight analogues via MDAP was 
unsuccessful (shown in black in Figure 5). The Chan-Lam coupling reaction did not 
proceed with 14 of the selected monomers shown in red in Figure 5. Monomers that 
failed to react were often structurally similar; these were monomers containing a 
heteroatom that was  to the reactive N-H, the majority of triazoles and most 
monomers that contained an unprotected hydroxyl group. It is thought that the failed 
reactions that fit into the first two descriptors were unsuccessful due to reduced Lewis 



























reaction.[10] The monomers containing hydroxyl groups likely failed due to a competing 
reaction between the N-H and O-H, leading to a reduced reaction rate and subsequent 
increase in the rate of protodeborylation and phenol formation by oxidation.[10] 
Nevertheless, the range of heteroaromatic coupling partners available for use in the 
Chan-Lam reaction has been considerably extended.  
With an array of potential integrin antagonists in hand, cell adhesion assays (n = 
2) were used to assess the potency and selectivity against v1, v3 and v6 
integrins, measuring the ability of compounds to inhibit the binding of the integrin 
(expressed on the surface of cells) to the endogenous peptide ligand.[33] The upper 
limit of the assay for v6 is pIC50 8.6 – 8.7, and a difference of more than 0.4 log units 
in compound potency is regarded as significant. Lipophilicity of the compounds was 
also determined by measuring the logD at pH7.4 chromatographically (ChromLogD 
pH7.4 ),[34] whilst high throughput permeability (HTP) was determined by the Parallel 
Artificial Membrane Permeation Assay (PAMPA).[35] Data for selected compounds 13-
23 are shown in Table 1. 
Related pyrazoles and imidazoles, for example the parent heterocycles and their 
mono-chloro derivatives, generally display similar levels of potency and selectivity, 
as demonstrated by 13-16, but differ in their high throughput permeability (HTP 
nm/s); each of the imidazole analogues analysed suffer from poor permeability, 
whereas the pyrazole analogues display modest to good permeability. This is due to 
the increased basicity of imidazoles compared to pyrazoles, leading to more basic 
and polar compounds that are considerably less permeable. This is supported by the 
observation that each pyrazole analogue exhibits a ChromLogD value that is at least 
0.6 log units greater than the corresponding imidazole analogue. Within the pyrazole 
series, comparison of 19 (5-methyl), 17 (3,5-dimethyl) and 18 (4,5-dimethyl) 
suggests that substitution at the 3 position,  to the sp2 nitrogen can provide an 
improvement in selectivity for the v6 integrin over the v3 integrin, with 4 and 5 
substitution providing no obvious advantage on either the potency or selectivity. The 
aliphatic amine analogues are generally less potent towards the v6integrin, with 
the exception of the piperidine analogue 22 which appears to be a potent v3and 
v6inhibitor. 
 













13  7.8 7.4 6.0 1.83 22 
14 
 
7.9 7.2 6.2 1.23 3 
15 
 
7.8 6.8 5.8 1.92 3 
16  8.0 6.8 6.3 2.61 86 
17 
 























7.3 7.0 - 2.65 17 
19 
 
7.6 7.3 - 2.17 13 
20  7.7 7.1 6.5 3.22 120 
21 
 
6.7 7.7 6.5 1.98 3 
22 
 
7.7 7.6 6.4 2.85 73 
23  7.3 7.6 6.4 2.84 88 
[a] HTP = high throughput permeability. 
 
The 3-chloro pyrazole analogue 16 was identified as a suitably lead-like compound, 
with high potency and excellent selectivity for v6 over v3 of 1.2 log units together 
with good permeability. This compound, along with the most permeable analogue, the 
3-isopropyl pyrazole derivative 20 and the aliphatic amine analogue with the highest 
potency towards v6 (22), were selected for further drug metabolism and 
pharmacokinetics (DMPK) studies. Thus, compounds 16, 20 and 22 were 
resynthesized on a larger scale using a modified route utilizing ethyl bromoacetate in 
the Reformatsky reaction rather than the tert-butyl ester, and installation of the 
heterocycles at an earlier stage (Scheme S1, Supporting Information). The three 
relevant Chan-Lam reactions were performed on 0.95 mmol scale, giving moderate 
yields ranging from 45-56%. On this larger scale, the minor 5-isopropylpyrazole 
regioisomer was isolated separately to the major regioisomer and the resulting 
combined yield was 77%. These compounds were N-deprotected and immediately 
subjected to amide coupling conditions with T3P. Following this, the compounds were 
subsequently N-deprotected and saponified to give the desired analogues 16, 20 and 
22. 
Initial DMPK studies reveal that in vitro these compounds have acceptable 
permeability and metabolic stability that complement their measured potency and 
selectivity profiles, further enhancing their potential as drug-like lead compounds 
(Tables S1 and S2, Supporting Information). For example, the piperidine analogue 22 
exhibits a moderate passive permeability (Papp = 9.7) and an efflux ratio of 8.2, and 
stability to Phase 1 metabolism in human liver microsomes, with a half-life of greater 
than 8 h. The additional data for piperidine 22 (Table S2) suggest that it, and related 
analogues, may have oral bioavailability.  
As one of the most selective compounds, 3-chloropyrazole 16 was docked into 
the v6 and v3 crystal structures (4UM9 and 1L5G respectively) to generate 

















Figure 6. Docked poses of 3-chloropyrazole analogue 16 in the v6 and v3 crystal structure (A and 
B respectively). Conformers were generated using OMEGA and subsequent docking was performed 
using FRED.[38,39] Visualization of conformers was performed using VIDA. The surface of the binding 
site is overlaid to show hydrophobicity; lighter areas are more hydrophobic and blue areas are more 
hydrophilic. Hydrogen bonds are displayed as dashed lines, showing coordination between the 1,8-
tetrahydronaphthyridine and Asp218, and the carboxylate with the metal ion in the metal ion dependent 
adhesion site (MIDAS). ADMIDAS = adjacent metal ion dependent adhesion site. 
 
Figure 6A shows the specificity determining loop (SDL) in the v6 binding site is 
relatively open and able to accommodate the chloro-pyrazole substituent. In 
contrast, Figure 6B, shows that there are four sidechains (labelled) in the v3 
integrin SDL that close off this pocket, preventing 16 binding in the conformation 
seen with v6 integrin, with Tyr166 and Arg214 being particularly influential. These 
residues limit the size of the pocket, and thus force the heterocyclic substituent into a 
more solvent exposed position, reducing overall binding affinity. Additionally, in this 
more solvent exposed position, the ADMIDAS manganese ion in the crystal structure 
of αvβ3 clashes with the chlorine atom in the pyrazole motif, further impacting binding 
affinity. In combination, these factors lead to the improved selectivity that is observed 
between the unsubstituted pyrazole 13 and those pyrazole analogues that contain a 
3-substituent (16, 17 and 18). 
 
Conclusion 
In conclusion, we have developed a late stage diversification of a complex, drug-like 
scaffold using a Chan-Lam copper catalyzed amination reaction. The key -aryl--
amino acid coupling partner was readily prepared on 15 g scale employing a 
A B 
B 
stereoselective Reformatsky addition to a sulfinimine, followed by Miyaura borylation 
to install the required pinacol borane motif. Subsequent Chan-Lam amination using 
an array of diverse and functionalized NH components led to the isolation and 
biological evaluation of a wide range of analogues. The compounds are potent v6 
integrin antagonists, and show some selectivity particularly vs. v1, with sufficiently 
acceptable permeability and metabolic stability to be considered as lead compounds 
for drug development. Our results extend the earlier work of Vantourout et al.[10] and 
establish a versatile strategy in a medicinal chemistry setting, which is amenable to 
high throughput array protocols. This thereby allows the installation of 
pharmaceutically valuable heteroaromatic fragments at a late stage by direct coupling 
to the NH heterocycles, leading to compounds with drug-like attributes, and is a useful 
addition to the medicinal chemist’s repertoire. 
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